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heterogeneity in the presence of vessel obstruction (1â€”3),
which is detected by myocardial perfusion imaging (4â€”6).
At present, dipyridamole and adenosine are the most com
monly employed pharmacological stress testing agents in
patients who are unable to perform adequate dynamic cx
ercise (7,8). The results of both adenosine and dipyridam
ole 201'flmyocardial imaging are comparable to those of
exercise studies for the detection and risk stratification of
coronary artery disease (CAD) (6â€”10).More recently, di
pyridamole and adenosine have been employed with good
results in conjunction with @Tc-labelodperfusion agents
(@â€˜Tc-sestamibi, @â€œ@Tc-teboroxime)(11â€”17).
Through induced blood flow heterogeneity, dipyridam
ole and adenosine may also produce true myocardial isch
emia (18â€”19),which can be recognized by the presence of
angina, ischemic ST-T changes on the electrocardiogram
and wall-motion abnormalities. Therefore, several groups
employed dipyridamole or adenosine echocardiography for
the detection of CAD, its evaluation and prognostic strat
ification (20â€”25).The published studies, however, report
variable results, probably because several factors influence
the actual induction of ischemia by dipyridamole and aden
osine. Therefore, studies performed in the same patient
population and possibly during a single pharmacological
stimulus are still needed. Until now, relatively few reports
fulfilled these requirements (26â€”31), and @Tc-sestamibi
perfusion imaging was used for the comparison in one
study only (32).
Furthermore, by using @Tc-labeledperfusion agents, a
new approach for the simultaneous evaluation of perfusion
and function is given by the collection of first-pass radio
nuclide angiocardiography (FPRNA) at the moment of
tracer injection (33â€”35).This approach has been proposed
and validated only for exercise FPRNA (36â€”38),but its use
in combination with dipyridamole and adenosine should be
even easier due to the absence of interferences from in
creased heart rate, patient motion and breathing.
The aims of the present study were: (1) to test the fea
sibiity of the simultaneous evaluation of perfusion and left
ventricular function using @â€œ@Tc-sestamibiin combination
The aimsofthisstudywere:(1) totestwhetherfirst-passradio
nuclideangiocardiography(FPRNA)addsusefulinformationto
perfusionscinhigraphy;and (2)to assessthe relativeaccuracyof
perfusion and functional imaging in combination wfth dipyndam
ole for the evaluation of CAD. Methods: Thirty patients wfth
angiographicallyprovenCAD (17wfthprior infarction)were stud
ied on separatedays at rest and with dipyridamoleinfusion (0.7
mg/kg over 4 mm).Tomographic images were evaluatedusing
an uptakescore. DipytidamoleFPRNAwas consideredpositive
in case of stress-inducedwall motionabnormalityor ejection
fractiondecrease.Results:The CADdetectionrateofperfusion
imaging was 100%, while that of FPRNA was 70% usIng wall
motioncriteria,63% usingejectionfractionresponseand 77%
consideringany abnormality.For CAD localization,perfusion
imaging showed 76% sensitivity, 96% specificity and 82% ac
curacy.FPRNAresultswere50%, 100% and60%, respectively.
Perfusionimagingwas significantlysuperiorto FPRNA also ex
dudingfromtheanalysistheinfarct-relatedvessels.FPRNAdid
not identifymultivesselCAD, whichwas correctlydetectedby
perfusion imaging in most cases. Both techniques were more
sensitivein case of 90% stenosis,but the differencewas more
remarkable for FPRNA (sensitivity 65% versus 14%, p <
0.0005).ConclusIons: DipytidamoleFPRNA did not add note
worthy clinical informationto perfusion imaging regardingCAD
detection and evaluationof disease extent. The main contribu
tion of a positive FPRNA was its relationwfth coronaty obstruc
tionseverity.These resultsconfirmthe superiorityof perfusion
overfunctionalimagingin combinationwithcoronaryvasodila
tors.
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oronary vasodilation by dipyridamole or adenosine
has been demonstrated to induce significant blood flow
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SPECT FPRNA
Patientno. Age/Sex Ml CAD RCA LAD LCX LAD LPD EF rest EF dipy
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Demographic, Clinical, Angiographic and Scintigraphic Findings of the Patient Population
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with dipyndamole infusion; (2) to verify whether dipyri
damole FPRNA adds useful data to perfusion scintigraphy
for the assessment of CAD extent and severity; and (3) to
gain new insight into the effectiveness of functional imag
ing in conjunction with coronary vasodilators.
METhODS
Patient Population and Study Protocol
The study population consisted of 30 patients, prospectively
recruited from those with known CAD, who were referred to our
nuclear medicine department for evaluation of angina which was
refractory to medical treatment. Patients with cardiac conditions
other than CAD (i.e., valvular disease, cardiomyopathy, etc.) or
with history of previous coronaiy angioplasty or bypass grafting
were excluded from the study population. There were 25 males
and 5 females, with ages ranging from 37 to 72 yr (mean 55.8 Â±
10.2yr). Seventeenpatientshadahistoryof previousmyocardial
infarction (anterior in 9 and inferior in 8). Table 1 lists the main
features of the patient population. Antianginal drugs were discon
tinued for 24hr (nitrates), 48 hr (calcium channel blockers) or 1wk
(beta-blockers) before entering the study. All subjects were in
structed not to consume drugs containing xanthine or substances
for 36 hr before the dipyridamole test. The clinical status of all
patients remained unchanged for the duration of the study. The
study protocol was approved by the ethics committee of our
institution and all patients gave informed consent to participate in
the study.
Thepatientsunderwenta baselineFPRNAstudyat the timeof
@Tc-sestamibiinjection. Patients then had a light meal and myo
cardial perfusion scintigraphy was performed beginning at least
1 hr after tracer injection (60â€”92mm). Twenty-four hours later
after overnight fasting, the patients underwent the dipyridamole
test (infusion ofO.7 mg/kgbodyweight over 4 min)(13,39). Patient
conditions during dipyridamole infusion were checked by contin
uous electrocardiographicmonitoringand blood pressure mea
surements at 1-mm intervals. As soon as the patient's typical
angina developed and/or horizontal depression of ST segment was
observed on the electrocardiogram, or 3 mm after the end of
dipyridamoleinfusion, @â€œTc-sestamibiwas injectedand FPRNA
acquired. Intravenous aminophylline(100mg) was given to all
patients 5 rain after the administration of @â€œTc-sestamibi,mdc
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FiGURE1. Schematicdrawingof the
methodusedto obtaina goodqualitybolus
injectionfor FPRNA.
pendent of adverse reactions. Myocardial scintigraphy was per
formed using the same procedure described for the rest study
(acquisition delay: 62â€”94mm after injection). Biplane coronary
angiography performed within 15days of the scinligraphic studies
was availablein all patients.
Coronary Anglography
Heart catheterizationwas performedusingeither the brachial
or the transfemoralapproach. Biplaneleftventricularcineangio
graphy was performed in the 30 degrees right anterior oblique
projection and in the 60 degrees left anterior oblique projection
using a pig-tail catheter. Left and right coronary angiograms were
acquiredin multipleprojectionsin order to identifythe presence
and severity of the lesions. A stenosis was classified as significant
whenever the vessel narrowingwas 50%and was classifiedas
severewheneveritwas 90%.Allstudieswerevisuallyevaluated
by an experiencedobserver who had no knowledgeof the pa
tient's identity or the results of the other examinations.
First-Pass Radlonuclide Anglocardlography
FPRNA was acquired in the 30 degrees right anterior oblique
projection, with the patient supine, using an Elscint Apex 5P4
gamma camera (Haifa, Israel) equipped with low-energy, all-pur
pose collimator and a 20% window centered on the 140 keV
photopeak of @â€œTc.In order to obtain a high quality bolus injec
tion, the following procedure was carried out. First, an 18-gauge
indwelling cannula was inserted into an antecubital vein of the
right arm (possibly the basilic vein) and connected with a saline
filledtubing extension endingwith a three-waystop-cock. 5cc
ond, a 0.5-mlsolutioncontainingthe doseof 20mCi(740MBq)of
@Tc-sestamibiwas injected into the tubing through the lateral
opening of the stop-cock, preceded and followed by a small air
bubble. Third, a syringewith 20 ml of saline solutionwas con
nected to the straight opening of the stop-cock. Fourth, after
having switched the stop-cock, the saline solution was smoothly
but forcefullyinjected,pushingthe tracer bolus in front of it into
the patient (Fig. 1). The bolus quality was controlled by the
time-activitycurveobtainedina regionofinterest (ROI)drawnon
the superior caval vein with good results (FWHM < 1 sec).
The studywas acquiredin framemode(24frames/sec),usinga
x2 zoom factor and an electrocardiographic gating for the recon
structionof the representativecardiaccycle. In the gammacam
era used, a 20% count rate loss is observed at count rates over
150,000counts/sec. A typical study collected approximately
120,000cps during the right phaseand 80,000counts/secduring
the left phase. Therefore, no significantcount losses were cx
pected.
The left ventricular ejection fraction was calculated from the
background-subtracted time-activity curve. Two measurements
were performedfor each study and the mean of the two values,
which never differed by more than 2 ejection fraction units, was
adopted for the data analysis. The reproducibility of FPRNA in
our laboratoryhad been previouslytested in anotherpatientpop
ulationby acquiringtwo separate studiesa few days apart under
stable clinicalconditionsand had been proven to be satisfactory
(Pearson's r = 0.94, s.e.c. = three ejection fraction units)
(35, DuPont: Data on File). The regional wall motion was ana
lyzed using the left ventricular end diastolic and end systolic
outlines with the aid ofthe representative cycle cine movie display
of the regionalejectionfractionimagesand of the Fourier ampli
tude images.
Myocardlal Perfusion Scintigraphy
Myocardial perfusion scintigraphy was performed using a dou
ble-headedgammacamera(Rotacamera,Siemens,Erlanger,Ocr
many)equippedwith ultra-highresolutioncollimatorsand inter
faced with a Hewlett Packard A900 computer system. A 20%
window centered on the @Tc140 keV photopeak was used.
SPECF was acquired using both heads, a 360Â°rotation arc in the
step-and-shoot mode with 90 projections of 20 sec each, and
recorded on 64 x 64 matrices. The SPED.' images were recon
structed using an iterative algorithmaccordingto the conjugate
gradient method (40,41), and were then reoriented according to
the heart axes so that short-axisand horizontaland vertical long
axis slices were obtained.
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FiGURE 2. Diagram showing the
adopted segment dMsion for FPRNA (left
panel) and perfusion imaging (right panel).
Theattributionofthesegmentstothediffer
ent vascularterriforiesis also shown.The
gray area in the middleof the three short
axis slices of perfusion imaging represents
thetwoa@ segmentsofthemid-ventric
ularverticallong-axisslice,whichwereused
to evaluatethe apicalperfusionandwere
assignedto the LAD.Ant. = anterior,lnf. =
inferior;lnf.-bas.= infero-basal;LAD = left
anterior descending artery; LCX = left cir
cumfiex artely; LPD = left posteriorde
scendingartery;and RCA = rightcoronary
artery.
I = antâ€¢rlor
2 = antâ€¢ro-septal
3 = lnfero-sptal
4 =inferior
5 = infero-lateral
6 =antero-lateral
Image Evaluation
The studies were independently evaluated by two experienced
observers who had no knowledge of the patient's history or the
results of the other examinations. In case of disagreement, the
images were reviewed with the help of a third observer and finally
classified by consensus.
For FPRNAanalysis,the leftventricularwallwas dividedinto
four segments (anterior, apical, inferior, infero-basal) (34) (Fig. 2).
On the basis of a qualitativeevaluation,the regionalwallmotion
of each segment was classffied normal, mildly hypokinetic, se
verely hypokinetic, akinetic or dyskinetic. The dipyridamole
study wasjudged positive for CAD in the presence ofeither a lack
of increase in left ventricular ejection fraction (39,42,43) and/or a
transient regional wall motion abnormality that was absent or of
lesser degree in the baseline study. For individual diseased vessel
localization, the results of FPRNA were evaluated by considering
only two vessel distributions (i.e., the left anterior descending
artery and the left posterior descending circulation, the latter
including both the right coronary and the left circumflex artery)
(Fig. 2).
SPECF perfusion images were evaluated qualitatively and the
tracer uptake was defined as normal, slightly reduced, severely
reduced or absent. Three short-axis slices (basal, mid-ventricular
and sub-apical) were divided into six segments each and consid
ered together with the antero-apical and the micro-apical seg
ments of the mid-ventricular long-axis slice (44) (Fig. 2). A fixed
defect seen unchanged on both rest and dipyridamole studies was
classified as an infarct scar. A decrease in uptake in the dipyri
damole myocardial scintigraphy as compared to the baseline pat
tern was considered inducible hypoperfusion in that territory. For
individual coronary artery localization, the various segments were
attributed to the three main coronary territories as proposed by
Kiat et al. (44) (Fig. 2).
To evaluatethe agreementbetweenthe two radionuclidetech
niques in the same vascular territories, SPECT and FPRNA seg
ments assigned to the left anterior descending artery were directly
compared, whereas the SPECF segments assigned to the right
coronary or left circumflex arteries were considered together and
compared with the segments attributed to the left posterior circu
lation in FPRNA.
Statistical Analysis
Sinceourpatientpopulationincludedonlysubjectswithknown
CAD, we did not estimate the diagnostic sensitivity or specificity
of the radionuclidestudies, but only the CAD detection rate.
Sensitivity for the identification ofindividual diseased vessels was
defined as the number of territories with abnormal findings di
vided by the total number of diseased territories. Specificity was
definedas the numberofterritorieswithnormalresultsdividedby
the total of territorieswithoutangiographicCAD.Data were cx
pressed when appropriate as the mean Â±s. d. The comparison of
baseline and dipyridamole hemodynamics was performed using
the two-tailedsignedranktest forpaireddata. For the comparison
of proportions,the Fisher's exact test was employed.The agree
ment of the two radionuclidetechniquesin evaluatingthe same
coronary territorieswas assessed by the McNemar's test. The
relation ofthe leftventricular ejection fraction response with CAD
extent and severity was analyzed by one-way analysis of variance
and by the Spearman'srank correlationcoefficient.A probability
value of p < 0.05was consideredsignificant.
RESULTS
Left Ventilcular and Coronary Anglography
Of the 17 patients with a history of prior myocardial
infarction, 16 had abnormal wall motion by left ventricular
cineangiography. An inferior and micro-lateral akinesia
was demonstrated in an additional patient, who had an
occluded left circumflex branch, but no history of previous
infarction. By coronary angiography, 9 patients had one
vessel CAD, 9 had two-vessel CAD and 12 had three
vessel CAD. Therefore, a total of 63 vessels presented a
50% stenosis.The left anteriordescendingarterywas
involved in 23 cases, the left circumflex artery in 21 and the
right coronary artery in 19 (with a total of 25 left posterior
descending circulations with CAD). A high grade (90%)
Dipyndamole @Tc-SestamibiImagingâ€¢SciagrÃ et al. 1257
(@A a@ LOQ
Lv
EDGES
[F
Hr'lFLIT
FIGURE 3. From left to nght baseline
and dipyridamoleperfusionimages;three
short-a)ds licesfromsubapical(toprow)to
basal,plusthe midventricularverticalkng
a)dsslice;andbaseline(rest)anddipyridam
ole FPRNAimages;leftventricularend-d@
stokeand end-systolicoutlines(LV edges),
regionalejectionfraction(reg.e.f.)and Fou
rier amplitude(amplit).An infero-lateralde
fact is seen in the baselinestudy, corre
sponding to an infero-basal severe
hypokinesis.After dipyridamole,this defect
worsensand enlargesand the region be
comesakinetic;furthermoreanapicaldefect
appears,accompaniedbyhypokinesisinthe
FPRNAimages.
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stenosis was observed in 29 arteries; if the left posterior
descending circulation was considered instead of the right
coronary artery and the left circumflex artery, however, a
total of 26 territories showed a 90% obstruction.
Hemodynamics and Adverse Reactions
The heart rate, systolic blood pressure values and rate
pressure product at the moment of the baseline study were
respectively: 66.4 Â±13.2 bpm, 137 Â±18.8 mmHg and
9,149 Â±2,606 bpm x mmHg. At the end of dipyridamole
infusion, the heart rate was 85.4 Â±16.9 bpm (p < 0.00001
versus baseline), the systolic blood pressure was 129 Â±
25.5 mmHg (p < 0.005 versus baseline) and the rate pres
sure product was 11,118 Â±3,963 (p < 0.0001 versus base
line). Mild and noncardiac adverse reactions (headache,
flushing and nausea) developed in 10 patients. In six pa
tients ischemic ST-segment changes on the electrocardio
gram were noted. In five of these patients typical angina
occurred. Both the noncardiac and the ischemic symptoms
and signs disappeared promptly after the routine adminis
tration of intravenous aminophylline.
Detection of Coronary Artery Disease
Table 1 shows the results of FPRNA and perfusion im
aging. Figures 3 and 4 show two examples of studies ob
tained in our patient population.
Eighteen perfusion defects in the baseline study were
observed in 16 subjects, involving 15 asynergic scars of
prior infarction and 3 territories related to diseased vessels,
but with normal wall motion in the contrast left ventricu
lography. Dipyridamole myocardial perfusion scintigraphy
was positive for stress-induced perfusion defects in all pa
tients (100% CAD detection rate) (Fig. 5).
Baseline FPRNA showed a wall-motion abnormality in
12 patients, 4 of whom also had an abnormal baseline
ejection fraction. The baseline abnormal territories in
volved 11 asynergic infarct scars and the already men
tioned asynergic territory without history of infarction.
Dipyridamole induced a wall-motion abnormality in 18 pa
tients. Therefore, considering the baseline and/or the di
pyridamole-induced wall-motion abnormalities, FPRNA
was positive in 21 patients (CAD detection rate: 70%, p <
0.001 versus perfusion imaging). The ejection fraction cri
teria for an abnormal response to dipyridamole were ful
filled in 19 patients (CAD detection rate: 63%, p < 0.0002
versus perfusion imaging). Overall, dipyridamole FPRNA
was positive in 23 patients (CAD detection rate: 77%, p <
0.01 versus perfusion imaging) (Fig. 5).
In the 13 patients without prior myocardial infarction,
dipyridamole FPRNA detected a wall-motion abnormality
in 8 (CAD detection rate: 62%, p < 0.02 versus 100% of
perfusion imaging). In seven of these eight patients and in
an additional patient, the ejection fraction response to di
pyridamole was abnormal (CAD detection rate using the
ejection fraction criteria: 62%, p < 0.02 versus perfusion
imaging). Overall, wall motion or the ejection fraction cri
teria for CAD was fulfilled in 9 of 13 patients without
previous infarction (CAD detection rate: 69%, p < 0.05
versus perfusion imaging) (Fig. 5).
In the 6 patients with typical angina and/or ischemic ST
segment changes in the electrocardiogram induced by di
pyridamole infusion, the overall CAD detection rate of
FPRNA was not significantly different from the value ob
served in the other patients (83% versus 75%).
Localization of Diseased Coronary Arteries
Of all territories (infarcted or not) with significant CAD,
perfusion imaging recognized 48 as diseased (sensitivity
76%) and was abnormal in one without significant stenoses
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(specificity 96%); thus, the overall accuracy was 82%.
FPRNA was abnormal in 24 of the 48 evaluated coronary
artery territories (sensitivity 50%, p < 0.005 versus perfu
sion imaging), but was never abnormal in a territory with
out significant coronary stenosis (specificity 100%, NS ver
sus perfusion imaging). The overall accuracy of FPRNA
was 60% (p < 0.0005 versus perfusion imaging) (Fig. 6).
A separate analysis was performed after excluding the
coronary arteries related to infarcted territories: thus, 73
vessels (46 with significant obstruction) were considered for
perfusion imaging and 43 (31 with significant obstruction)
were considered for FPRNA. The sensitivity of perfusion
imaging was 67% and that of FPRNA 35% (p < 0.01); the
specificity was 96% and 100%, respectively (NS), and the
accuracy 78% and 53%, respectively (p < 0.01) (Fig. 6).
FIGURE 4. Same imagedispositionas in
Figure2. Baselineperfusionand FPRNA
are normal.Afterdipyridamole,bothan an
tero-apicaland an inferior defect appear,
whereasFPRNArem@nsnormal.
Figure 7 shows the agreement of SPECT perfusion scin
tigraphy and FPRNA for the evaluation of the same coro
nary artery territories. The significant difference between
the two techniques is apparent, taking into account all
territories and excluding those with previous infarction.
Assessment of Extent of Coronary Artery Disease
In 15 of 21 patients with multivessel CAD, uptake de
fects were demonstrated by perfusion imaging in more than
one territory. More specifically, of the 9 patients with two
vessel CAD, 6 were correctly classified by SPECT and 3
were found to have one-vessel disease. Of the 12 patients
with three-vessel CAD, 4 were correctly classified, 5 were
found to have two-vessel disease and 3 showed a single
vessel involvement. FPRNA detected a wall-motion ab
FiGURE5. Barhistogramshowingthe
CAD detection rate of perfusion imaging
(SPEd) and FPRNA, considering respec
tivelythe wail motioncriteria(FP-WM),the
ejectionfraction response(FP-EF)or the
presenceof any abnOrmality(FPRNA).@
p < 0.01;â€œ= p < 0.001;â€œ@= p < 0.0002;
# = p < 0.02;## = p < 0.05;(allversus
perfusionimaging).
All @ents Patientswithout
previousInfarction
SPECTFP-WM FP-EF FPRNA SPEd FP.WM FP.EF FPRNA
RadIOnUclidet chnique
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normality of both examined territories in only 3 patients
(p < 0.001 versus perfusion imaging). Examining only the
patients without previous infarction, perfusion imaging
correctly classified 4 of 5 multivessel patients and FPRNA
classified none of them (p < 0.05 versus perfusion imag
ing). Neither the analysis of variance nor the Spearman's
correlation coefficient demonstrated any relation between
the dipyridamole-induced changes of the left ventricular
ejection fraction and the number of diseased vessels.
Assessment of Coronary Stenosis Severity
A perfusion defect was observed in 26 of the 29 arteries
with a high-grade stenosis (90% of vessel lumen) (sensi
tivity 90%) and in 22 of the 34 with a <90% obstruction
(sensitivity 65%, p < 0.02). A wall-motion abnormality was
detected by FPRNA after dipyridamole in 17 of the 26
territories considered for this investigation which pre
sented a 90% lesion (sensitivity 65%), and in only 3 with
a <90% obstruction (sensitivity 14%, p < 0.0005). Limiting
the analysis to the diseased vessel in territories without
prior infarction, perfusion imaging was positive in 15 of 19
with 90% obstruction (sensitivity 79%) and in 16 of 27
with <90% narrowing (sensitivity 59%, NS). FPRNA was
FiGURE 6. Bar histogram showing the
resutis of dipyiidamoleperfusionimaging
(SPECT) and FPRNA for CAD localization,
respectively,consideringall vessels (left
groupof bars)and exdudingthe infarct-re
latedarteries(rightgroup).@ p < 0.005;
** = p < 0.0005; # = P < 0.01. Sensitivity Speclficfty Accuracy Sensitivity Speclflcfty Accuracy
positive in 8 of 16vessels with 90% (sensitivity 50%) and
in 3 of 15 with <90% obstruction (sensitivity 20%, NS).
Figures 8 and 9 show the agreement of the two radionu
cide techniques in the detection of coronary involvement,
taking into account the severity of vessel narrowing and
either including or excluding the territories with prior in
farction. A significant difference between perfusion and
FPRNA was found in stenoses @50%and <90%, but was
no longer observed in obstructions 90%, independently
from the presence ofprevious infarction. Both the one-way
analysis of variance (p = 0.08) and the Spearman's cone
lation coefficient (â€”0.31,p = 0.09) showed a trend to a
different response of left-ventricular ejection fraction to
dipyridamole infusion in the patients with at least one Se
vere stenosis compared to the others, although the statis
tical significance was not attained.
DISCUSSION
Dipyridamole or adenosine perfusion scintigraphy has
been proven to be accurate for the diagnosis of suspected
CAD and effective for prognostic stratification (6â€”17).
Since the blood flow heterogeneity produced by these
FiGURE 7. Agreement for dassification
of indMdualcoronaryvesselsbetweenper
fusionimaging(SPECT)and FPRNAin the
leftanteriorand leftpostenordescending
territories.The leftdiagramindudesall tern
tories,therightonlythosewfthoutprevious
infarction.
1260 The Journalof NuclearMedicineâ€¢Vol.35 â€¢No. 8 â€¢August1994
SPECT SPECT
+ â€¢ +
+ 17 0 + 8 0
FPRNA FPRNA
â€¢ 5 0 - 4 0
N.S. N.S.
SPECT
+ - +
+ 2 0 + 2 0
FPRNA
13 7 8 6
â€”
p<0.001 pcO.02
FIGURE 8. Agreementfor classification
ofindMdualcoronaryartenesbetweenper
fusionimaging(SPECT)andFPRNAinyes
selswith 50%and <90% obstruction;the
left diagramincludesall of them, the nght
Onlythosewithoutpreviousinfarction.
agents may induce myocardial ischemia, their use in com
bination with imaging techniques, which can detect isch
emic wall-motion abnormalities, has been proposed (20).
Unfortunately, dipyridamole and adenosine induce actual
ischemia in only a limited number of cases. In an animal
model of single-vessel obstruction, Fung et al. (19) dem
onstrated that dipyridamole induced a blood flow hetero
geneity in all animals by producing a higher increase of
flow in the normal than in the stenosed territory; however,
a true reduction of coronary blood flow followed by actual
ischemia was observed only in about 50% of cases. In
humans, several factors may influence the induction of
myocardial ischemia by dipyridamole or adenosine.
Among them are the extent and severity of CAD (43,45),
the concomitant antianginal therapy (46) and the dosage of
dipyridamole and adenosine (21). Therefore, it is not sur
prising that the value of functional changes induced by
dipyridamole or adenosine is far less established than that
of perfusion abnormalities. Most data have been obtained
employing two-dimensional echocardiography and the re
ported sensitivity values vary substantially, ranging from
10% (28) to 85% (22) for the adenosine test and from 40%
(30) to 90% (24) using dipyridamole. With regard to equi
librium radionuclide angiocardiography, Harris et al. (47)
found only a 13% sensitivity of dipyridamole testing for the
diagnosis of CAD. This number increased to 31% in the
study of Sochor et al. (48), whereas Cates et al. (39), using
a higher dipyndamole dosage and less stringent positivity
criteria, were able to detect CAD in 67% of cases. Even
better results were reported by Klein et al. who concluded
that a true dipyridamole-induced ischemia is present in
most patients (43). These authors also suggested a relation
between the extent and severity of CAD and the left-yen
tricular ejection fraction response (43). More homoge
neous data are reported about the specificity of adenosine
and dipyridamole functional imaging, with values con
stantly over 85% (21,24,39).
However, relatively few data are available comparing
perfusion and functional changes caused by a single phar
macological stress in the same patient population. Using
the collection of echocardiographic images and the injec
tion of 20111during a single adenosine infusion, Nguyen et
al. (28) found a very low sensitivity of echocardiography
(10%) compared to perfusion imaging (88%). Using a sim
ilar approach and dipyridamole infusion, LabOVitZet al.
(26) demonstrated a 74% sensitivity of echocardiography
for the detection of 20â€•flperfusion defects. Jain et a!. (27)
performed the comparison after the oral administration of
dipyridamole, observing a positive echocardiographic
study in 14 of 16 patients with a perfusion defect in 201'fl
scintigraphy. Perin et al. (29) found a significant superiority
of dipyridamole 201'flover echocardiography both with
regard to detection of CAD and to evaluation of its extent.
Finally, in the only published study employing @â€˜@Tc-ses
tamibi perfusion scintigraphy, Marwick et al. (32) found
that the sensitivity of adenosine echocardiography was
FiGURE 9. Agreement for classification
of indMdualcoronaryarteriesbetweenper
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58% in front of 86% for perfusion imaging. In the same
patients, dobutamine echocardiography achieved 85% sen
sitivity and the authors suggested that this is the best phar
macologic stressor for functional imaging (32). All these
studies seem to indicate that functional imaging combined
with dipyridamole or adenosine infusion is only a moder
ately sensitive test for the evaluation of suspect CAD.
The use of @Tc-labeledperfusion agents has opened
the way to the simultaneous assessment by radionucide
imaging of perfusion and function during single stress. Var
ious studies have already demonstrated the feasibility of
this approach during dynamic exercise testing (36â€”38).
This combined evaluation should be even simpler during
dipyridamole or adenosine stress, since the patient may be
studied supine and no artifacts due to patient's motion,
increased heart rate and increased breathing frequency
should be expected. Also, by taking the above mentioned
limitations of dipyridamole functional imaging into ac
count, the possibility of achieving additional useful infor
mation without increasing the radiation burden for the pa
tient should be considered.
In the present study, the feasibility of a similar approach
and its clinical value for the identification of CAD and the
definition of its extent and severity in patients with effort
angina have been tested. Our study shows that FPRNA
with @Tc-sestamibiin combination with dipyridamole in
fusion is easily feasible and that the higher dose compared
to the usual protocol for dipyridamole perfusion scintigra
phy, which is necessary for a reliable functional study,
does not cause any problem in terms of adverse effects, in
accordance with previous reports (13,21,39). For the iden
tification of CAD, however, our results show that in front
of the extremely high CAD detection rate obtained by
perfusion imaging, dipyridamole FPRNA-detected wall
motion abnormalities in 70% of patients and reached a
slightly higher detection rate only when the changes of the
left ventricular ejection fraction were also taken into ac
count.
As for the extent of CAD, which is a major task of
imaging techniques in patients with known disease, perfu
sion imaging allowed correct identification in most patients
affected by multivessel CAD and accurate classification of
the individual vessel status. On the contrary, FPRNA ob
tained poor results in both cases. These trends, observed in
the whole patient population, were also demonstrated after
having excluded the patients with previous infarction, and,
respectively, the coronary arteries related to infarcted ter
ritories. The left ventricular ejection fraction response,
which improved the first-pass detection rate, appeared Un
able to differentiate reliably between patients with one
vessel disease from those with multivessel disease. Thus,
in our patient population and independent of prior infarc
tion, FPRNA data did not improve the coronary disease
detection rate and extent evaluation achieved by dipyri
damole perfusion imaging. These data support the conclu
sion that dipyridamole radionuclide angiocardiography
alone has no practical role in the work-up of CAD
and confirm that the radionudide technique to be used with
coronary vasodilators is perfusion scintigraphy (49).
We also tested the influence of the severity of coronary
artery stenosis on the perfusion and FPRNA results. Both
techniques were more sensitive in cases of high-grade ob
struction. The gain was more remarkable for FPRNA, so
there was no significant difference of sensitivity compared
to perfusion imaging for the detection of 90% stenoses.
Therefore, the positivity of dipyridamole FPRNA sug
gested the presence of severe narrowing of coronary arter
ies related to that territory. Similar data were obtained by
taking into account only the vessels without prior infarc
tion. Interestingly, the left ventricular ejection fraction also
showed a clear, albeit not statistically significant, trend to
respond more abnormally in the patients with at least one
severe stenosis compared to the others. Taking these last
data into account, however, the technical effort of collect
ing FPRNA during @â€˜Tc-sestamibiperfusion imaging with
dipyridamole hardly seems justified by the achievable ad
ditional information.
Various limitations of the present study must be taken
into account. The patient population was relatively small
and highly selected, including only patients with known
CAD. Therefore, no data could be obtained about the
specificity of the employed techniques for the diagnosis of
disease. A second selection drawback was that several
patients had a history of prior infarction. In our opinion,
however, this population represents a more realistic sam
plc for the use of imaging techniques devoted to the defi
nition of CAD extent and severity than a population of
subjects in whom the diagnosis itself is still uncertain.
Furthermore, the separate analysis of the data, after having
excluded the patients or the vessels with prior infarction,
fully confirmed the results obtained in the whole popula
tion. Finally, our data are in good agreement with those of
Marwick et al. (32) who examined only patients without a
history of infarction. However, caution must be paid in
extending our results to other techniques of functional im
aging with dipyridamole or adenosine. Indeed, FPRNA has
several disadvantages for wall-motion abnormality detec
tion when compared to echocardiography, such as the cx
tremely short time interval which can be examined and the
impossibility of evaluating the changes of systolic thicken
ing. More importantly, FPRNA does not allow an accurate
evaluation of the wall-motion in the nontangential seg
ments, which are the septum and the lateral wall when the
30Â°right anterior oblique view is employed. However, the
use of regional ejection fraction images improves the anal
ysis ofwall-motion changes also in nontangential segments
(50). On the other hand, FPRNA also offers remarkable
advantages, such as allowing a reliable estimate of the
quantitative changes in global function induced by the
pharmacological stress, being highly reproducible and less
observer-dependent (34,35,51 ). Furthermore, the presence
of a majority of patients with severe and extensive CAD
and the absence of antianginal therapy were both circum
stances which should have theoretically increased the rate
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of dipyridamole-induced ischemic changes to the highest
level (43,46). The evaluation of the impact of other advan
tages of echocardiography such as ease, safety, wide avail
ability and lower costs compared to nuclear medicine tech
niques was beyond the scope of this study.
In conclusion, dipyridamole FPRNA appeared to be of
limited value for CAD detection and assessment of disease
extent when compared to perfusion imaging. Specifically,
the collection of FPRNA in the context of dipyridamole
myocardial scintigraphy with @â€œ@Tc-sestamibidid not add
important information to the perfusion images. More gen
erally, this study seems to confirm that, with the exception
of the high specificity, the reliability of functional imaging
in conjunction with dipyridamole is significantly lower than
that of perfusion imaging, even in a population with severe
and diffuse CAD studied in therapeutic washout.
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